
GRI Bio, Inc.
93
Recent developments include reiteration of full year 2025 financial results with balance sheet strengthening, completion of patient enrollment in Phase 2a study of GRI-0621 with positive interim safety and biomarker results, and securing new U.S. patents covering novel compound structures.
- GRI Bio reiterated full year 2025 financial results and reported strengthening of its balance sheet [N1].
- The company completed patient enrollment in its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis, with interim results showing safety and tolerability [N3].
- Positive interim safety results for GRI-0621 in the Phase 2a IPF study were reported, supporting continued development [N4].
- GRI Bio reported positive Phase 2a interim safety and biomarker results for GRI-0621 in IPF treatment, indicating potential anti-fibrotic effects [N6].
- The company secured a new U.S. composition of matter patent covering novel compound structures, enhancing its intellectual property portfolio [N2].
- CEO Marc Hertz participated in investor events discussing clinical advancements and company strategy [N5][N7].
- GRI Bio anticipates key Phase 2a data readouts for GRI-0621 and has secured cash runway for operations [N8].
GRI Bio, Inc. focuses on developing innovative therapies for diseases caused by dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders. The company's lead product candidate, GRI-0621, is an oral formulation targeting type 1 invariant natural killer T cells, being developed primarily for idiopathic pulmonary fibrosis (IPF). IPF is a progressive lung disease with limited treatment options and significant unmet medical need. GRI-0621 has undergone Phase 2a clinical trials demonstrating safety and biomarker signals consistent with anti-fibrotic effects. The company also develops GRI-0803, targeting autoimmune diseases such as lupus. GRI Bio has a proprietary compound library and has engaged in multiple capital raises and patent filings to support its pipeline and operations.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies targeting immune dysregulation in fibrotic and autoimmune diseases. Its lead candidate, GRI-0621, is an oral inhibitor of iNKT cells in Phase 2a trials for idiopathic pulmonary fibrosis, showing safety, tolerability, and biomarker evidence of anti-fibrotic activity. The company reported a net loss of $1.506 million and strong liquidity with $9.47 million cash as of September 30, 2026. Recent developments include patent grants, clinical enrollment completion, and capital raises. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
GRI Bio's lead candidate GRI-0621 has demonstrated safety and biomarker evidence of anti-fibrotic activity in Phase 2a trials for IPF, a disease with high unmet need. Positive clinical data and biomarker signals support further development and potential regulatory pathways in the U.S. and EU. The company’s expanding patent portfolio and proprietary compound library provide a foundation for pipeline growth. Strong liquidity and recent capital raises support ongoing operations and clinical programs. Management engagement with investors and strategic patent filings indicate active execution.
GRI Bio remains a clinical-stage company with no approved products and ongoing reliance on capital markets for funding. Clinical trial results, while positive on safety and biomarkers, are preliminary and require confirmation in larger studies. The company faces risks typical of biotech, including regulatory hurdles, clinical trial uncertainties, and competitive pressures. The net losses and limited revenue generation highlight financial risks. The success of pipeline candidates such as GRI-0803 is uncertain and dependent on future development milestones.
GRI Bio's moat is based on its proprietary oral formulation of tazarotene (GRI-0621) targeting iNKT cells, a novel mechanism in fibrotic lung diseases like IPF where current therapies have limitations. The company has a growing patent portfolio including U.S. and European patents covering novel compound structures and NKT cell modulators, which may provide intellectual property protection. Its clinical-stage pipeline and specialized focus on immune modulation in fibrotic and autoimmune diseases contribute to its competitive positioning. However, as a clinical-stage biopharma, the moat depends on successful clinical development and regulatory approvals.
• Clinical Development Risk: GRI Bio's lead product candidate GRI-0621 is in early clinical stages; failure to demonstrate efficacy or safety in later trials could impact the company's prospects.
• Regulatory Risk: Advancement to Phase 2b and potential conditional approvals depend on regulatory agency clearances and compliance with clinical trial requirements.
• Financial Risk: The company reported net losses and depends on capital raises to fund operations; insufficient funding could delay development programs.
• Market and Competitive Risk: IPF and autoimmune disease treatment markets are competitive with existing therapies; GRI Bio's products must demonstrate clear advantages to gain adoption.
• Intellectual Property Risk: While the company has patents, challenges or expiration could affect competitive positioning and exclusivity.
Business trends: Continued clinical development of GRI-0621 for IPF with biomarker and safety data supporting anti-fibrotic activity; expansion of patent portfolio and pipeline compounds targeting autoimmune diseases.
Execution milestones: Completion and analysis of Phase 2a trial data; initiation of Phase 2b trials subject to regulatory clearance and funding; advancement of IND-enabling studies for GRI-0803.
Key risks: Clinical trial outcomes and regulatory approvals remain uncertain; financial sustainability depends on capital raises; competitive and intellectual property challenges in biopharmaceutical development.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies targeting serious diseases with dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders [S1].
- The company's lead product candidate is GRI-0621, an oral inhibitor of type 1 invariant natural killer T (iNKT) cells, formulated as an oral form of tazarotene, a synthetic retinoid acid receptor-beta and gamma selective agonist [S1].
- GRI-0621 is being developed primarily for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease affecting approximately 140,000 people in the U.S. with up to 40,000 new cases annually [S1].
- GRI-0621 has been evaluated in a randomized, double-blind, multi-center Phase 2a clinical trial in IPF patients, with primary endpoints of safety and tolerability, and secondary endpoints including biomarker and pharmacodynamic assessments [S1].
- The Phase 2a trial enrolled 35 patients, with 19 completing treatment on GRI-0621 and 9 on placebo; the trial met its primary endpoint with no treatment-related serious adverse events reported [S1].
- Adverse events in the trial were mostly grade 2 or 3, including dry skin, dry lips, muscle and joint pain; no increases in cough or gastrointestinal disorders were observed in the treatment arm compared to placebo [S1].
- Biomarker data from the trial suggested anti-fibrotic effects, including decreases in fibrosis formation markers and increases in fibrosis resolution markers after 12 weeks of treatment [S1].
- Functional lung capacity (FVC) showed placebo-adjusted increases in the GRI-0621 arm, with 39% of treated subjects experiencing FVC improvement versus 80% decline in placebo subjects [S1].
- Gene expression and immune cell activity analyses indicated inhibition of iNKT cell activity and modulation of immune responses consistent with anti-fibrotic effects [S1].
- The company plans to use Phase 2a results to inform dose, safety, sample size, and clinical trial design for future Phase 2b trials, potentially supporting conditional approval in the EU and registrational status in the U.S., subject to FDA clearance and funding [S1].
- GRI Bio also has a pipeline including GRI-0803, an oral agonist of type 2 diverse Natural Killer T cells, targeting autoimmune disorders such as lupus and multiple sclerosis; IND-enabling studies and Phase 1 trials are planned [S1].
- The company has a proprietary library of over 500 compounds for potential development [S1].
- GRI Bio has conducted multiple reverse stock splits between 2024 and 2026 to consolidate shares [S1].
- The company completed securities purchase agreements in 2024 and 2025, raising capital through public offerings and warrant issuances, with placement agents including H.C. Wainwright & Co. [S1].
- As of September 30, 2026, GRI Bio reported cash and cash equivalents of approximately $9.47 million, current assets of $9.73 million, and current liabilities of $0.95 million, resulting in a current ratio of 10.21 and a cash ratio of 9.94, indicating strong liquidity [S2].
- Net income for the quarter ended September 30, 2026, was a loss of $1.506 million, with basic and diluted EPS of -$0.69 per share [S2].
- Recent news highlights include reiteration of full year 2025 financial results and balance sheet strengthening, completion of patient enrollment in Phase 2a study of GRI-0621 with positive interim safety and biomarker results, and securing new U.S. patents covering novel compound structures [N1][N2][N3][N4][N6].
- The CEO has participated in investor presentations discussing advancements in NKT cell modulators and clinical progress [N5][N7].
- The company has advanced its global patent strategy with European patent grants for NKT cell modulator innovations [N1].
Generated 2026-11-14
- S1 | 2026-01-30 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-02-04 | www.globenewswire.com | GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | https://globenewswire.com/news-release/2026/02/04/3232071/0/en/GRI-Bio-Reiterates-Full-Year-2025-Financial-Results-Strengthens-Balance-Sheet-and-Summarizes-Key-Recent-Highlights.html
- N2 | 2026-01-26 | www.globenewswire.com | GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures | https://www.globenewswire.com/news-release/2026/01/26/3225639/0/en/GRI-Bio-Secures-New-U-S-Composition-of-Matter-Patent-Covering-Novel-Compound-Structures.html
- N3 | 2025-07-01 | www.nasdaq.com | GRI Bio, Inc. Completes Patient Enrollment in Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis, Interim Results Show Safety and Tolerability | https://www.nasdaq.com/articles/gri-bio-inc-completes-patient-enrollment-phase-2a-study-gri-0621-idiopathic-pulmonary
- N4 | 2025-06-26 | www.nasdaq.com | GRI Bio, Inc. Reports Positive Interim Safety Results for GRI-0621 in Phase 2a Study for Idiopathic Pulmonary Fibrosis | https://www.nasdaq.com/articles/gri-bio-inc-reports-positive-interim-safety-results-gri-0621-phase-2a-study-idiopathic
- N5 | 2025-05-16 | www.nasdaq.com | GRI Bio, Inc. CEO Marc Hertz to Participate in Live Webcast Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025 | https://www.nasdaq.com/articles/gri-bio-inc-ceo-marc-hertz-participate-live-webcast-fireside-chat-agps-annual-healthcare
- N6 | 2025-05-15 | www.nasdaq.com | GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment | https://www.nasdaq.com/articles/gri-bio-inc-reports-positive-phase-2a-interim-safety-and-biomarker-results-gri-0621
- N7 | 2025-03-18 | www.nasdaq.com | GRI Bio, Inc. CEO Marc Hertz Discusses Advancements in NKT Cell Modulators for IPF in Recent Virtual Investor Segment | https://www.nasdaq.com/articles/gri-bio-inc-ceo-marc-hertz-discusses-advancements-nkt-cell-modulators-ipf-recent-virtual
- N8 | 2025-03-17 | www.nasdaq.com | GRI Bio, Inc. Anticipates Key Phase 2a Data Readouts for GRI-0621 in 2025 While Securing Cash Runway for Operations | https://www.nasdaq.com/articles/gri-bio-inc-anticipates-key-phase-2a-data-readouts-gri-0621-2025-while-securing-cash
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


